Angela Sabry, MD
Allergy · Fresno, CANPI 1811297427
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (49.1%), food and beverage and consulting fees — rather than concentrated in one kind of arrangement. AstraZeneca accounts for 60.9% of it on its own, with 30 other manufacturers making up the rest. 2025 is the largest year on record at $21,328, more than ten times the $1,451 reported in 2019. Among allergy clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 480 payments — averaging $69.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$20K
- Genentech USA, Inc.$5K
- GSK$2K
- Regeneron Healthcare Solutions, Inc.$779
- Amgen$679
- Takeda Pharmaceuticals U.S.A., Inc.$599
- plus $4K from 25 others
What the payments were for
- Consulting fees$3,76911%
- Speaking & faculty fees$16,40049%
- Travel & lodging$2,4907%
- Food & beverage$10,49031%
- Education$2391%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 105 | $20,319 |
| Genentech USA, Inc. | 9 | $5,100 |
| GSK | 102 | $1,573 |
| Regeneron Healthcare Solutions, Inc. | 33 | $779 |
| Amgen(2 entities) | 35 | $679 |
| Takeda Pharmaceuticals U.S.A., Inc. | 24 | $599 |
| Biocryst US Sales Co., LLC | 22 | $597 |
| Incyte Corporation | 21 | $536 |
| CSL Behring | 23 | $536 |
| Novartis | 16 | $411 |
| Octapharma USA, Inc. | 11 | $370 |
| Pfizer | 13 | $275 |
| Optinose US, Inc. | 12 | $233 |
| Boehringer Ingelheim | 7 | $146 |
| Greer Laboratories, Inc. | 5 | $130 |
| Sanofi | 6 | $128 |
| Alk-abello, Inc | 1 | $125 |
| Pharming Healthcare, Inc. | 4 | $115 |
| ARS Pharmaceuticals Operations, Inc. | 5 | $113 |
| Shire North American Group Inc | 4 | $87 |
| Ionis Pharmaceuticals, Inc. | 3 | $85 |
| Kaleo, Inc. | 4 | $82 |
| Teva Pharmaceuticals USA, Inc. | 4 | $80 |
| Cycle Pharmaceuticals Inc | 2 | $68 |
| Abbott | 2 | $60 |
| LEO Pharma Inc. | 2 | $49 |
| Galderma Laboratories, L.p. | 1 | $30 |
| Paratek Pharmaceuticals, Inc. | 1 | $25 |
| ADMA Biomanufacturing LLC | 1 | $24 |
| Ultragenyx Pharmaceutical Inc. | 1 | $20 |
| Grifols USA, LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$33,388 in reported general payments places this provider in the 90th percentile of 117 allergy providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XolairOmalizumab | 13 | $29,671 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 15 | $15,619 |
| Breo ElliptaFluticasone/Vilanterol | 17 | $8,073 |
| Azelastine Hcl | 68 | $3,030 |
| BreynaBudesonide/Formoterol Fumarate | 12 | $2,694 |
| Epinephrine | 16 | $2,037 |
| Fluticasone Propionate | 63 | $1,169 |
| Ipratropium Bromide | 20 | $679 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 24 | $662 |
| Levocetirizine Dihydrochloride | 12 | $546 |
| Montelukast Sodium | 42 | $526 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 15 | $85 |
| Prednisone | 17 | $20 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GSKTrelegy Ellipta, Breo Ellipta | $1,573 | $23,69232 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 117 allergy providers in California.
Other allergy in Fresno
- Howard PettigrewFresno$3K
- Malik BazFresno$2K
- Joshua JacobsWalnut Creek$1.5M
- Warner CarrLaguna Niguel$571K
- Bradley ChippsSacramento$571K
- Travis MillerRoseville$273K
- Robert ZeigerSan Diego$162K
- William BergerMission Viejo$76K
- Sandra ChristiansenSan Diego$74K
- Stephen WongHacienda Heights$50K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.